Key Points
- Maze Therapeutics insider Atul Dandekar sold 7,500 shares at an average price of $32.07, generating $240,525. The Rule 10b5-1 transaction reduced his holdings by 18.84% to 32,316 shares.
- MAZE opened at $31.48, with a $1.75 billion market capitalization and a 12-month trading range of $21.95 to $53.65. The company reported a quarterly loss of $0.76 per share, in line with analyst expectations.
- Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $64.45, while major institutions including ARCH Venture Management, Alphabet, and TRV GP IV recently established or increased positions.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $32.07, for a total transaction of $240,525.00. Following the completion of the sale, the insider owned 32,316 shares in the company, valued at approximately $1,036,374.12. This trade represents a 18.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Atul Dandekar also recently made the following trade(s):
- On Tuesday, September 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.06, for a total transaction of $202,950.00.
- On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $84,350.43.
- On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total transaction of $84,465.77.
- On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.58, for a total value of $206,850.00.
Maze Therapeutics Stock Performance
Shares of Maze Therapeutics stock opened at $31.48 on Friday. The stock's fifty day simple moving average is $27.49 and its 200 day simple moving average is $31.99. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $1.75 billion, a PE ratio of -12.49 and a beta of 2.16. Maze Therapeutics, Inc. has a 12 month low of $21.95 and a 12 month high of $53.65.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.76). On average, research analysts predict that Maze Therapeutics, Inc. will post -2.70 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on MAZE. BTIG Research reiterated a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Citigroup began coverage on shares of Maze Therapeutics in a report on Wednesday, September 23rd. They set a "buy" rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $110.00 price target on shares of Maze Therapeutics in a research note on Thursday, September 24th. Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Three investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $64.45.
Read Our Latest Research Report on MAZE
Institutional Trading of Maze Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of MAZE. ARCH Venture Management LLC bought a new stake in shares of Maze Therapeutics in the second quarter valued at about $122,983,582. Alphabet Inc. bought a new position in shares of Maze Therapeutics during the second quarter worth about $41,435,000. TRV GP IV LLC bought a new position in shares of Maze Therapeutics during the second quarter worth about $133,502,907. Frazier Life Sciences Management L.P. raised its position in Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company's stock valued at $150,182,000 after buying an additional 465,641 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new stake in Maze Therapeutics in the 2nd quarter valued at approximately $101,764,000.
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.
Maze's pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
